CRMD vs GTE
CRMD: A commercial-stage biopharmaceutical company focused on preventing catheter-related bloodstream infections and delivering a portfolio of hospital-based anti-infective therapies. GTE: An international oil and gas explorer and producer focused on asset development in Colombia, Ecuador, and Canada.
Side-by-side fundamentals
| Metric | CRMD | GTE | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $5.70 | $11.33 | |
| Market cap | $444M | $401M | |
| P/E as of 2026-10-30 | 2.61 | n/a | |
| Net margin FY2025, SEC XBRL | +52.3% | -32.4% | CRMD higher |
| Gross margin FY2025, SEC XBRL | +88.5% | n/a | |
| Operating margin FY2025, SEC XBRL | +48.2% | n/a | |
| ROE FY2025, SEC XBRL | +40.2% | -84.4% | CRMD higher |
| ROA FY2025, SEC XBRL | +19.7% | -12.2% | CRMD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 4.00 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +617.0% | -4.0% | CRMD higher |
| Revenue CAGR (3y) SEC XBRL | +535.6% | -5.7% | CRMD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.87 | 0.57 | |
| 1-year return as of 2026-10-30 close | -51.0% | +207.0% | GTE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.